Drugmakers turn up marketing efforts in diabetes market
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
Pharmaceutical
Articles
China bribery probe leading to tough drug market, CEO says
Drugmakers under investigation for bribery have stopped promoting products in China, and physicians in some hospitals no longer want to meet sales representatives. Eli Lilly is among the drugmakers in China facing allegations.
Indiana board considers 1-year delay of patient tests
Indiana's Medical Licensing Board is considering delaying for one year a proposed new rule that would require physicians to conduct annual toxicology tests on some patients as part of a larger state effort to crack down on prescription drug abuse.
Doctor charged with overprescribing painkillers
Dr. Segun Rasaki, 49, prescribed drugs like hydrocodone and methadone to people who didn’t need them, and submitted fraudulent insurance claims such as duplicate billings, according to court documents.
Lilly lung cancer drug raises patient survival in trial
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
Lilly aims potential Alzheimer’s drug at early patients
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
Rx benefits manager plans to hire 205 by 2015
Lisle, Ill.-based Catamaran Corp. has committed to hiring 104 full-time, permanent employees next year and a total of 205 by 2015.
Lilly drug for Alzheimer’s gets limited Medicare coverage
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Lilly’s Lechleiter back at helm after health scare
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
Lilly wins patent lawsuit on J&J Alzheimer’s research
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
Lilly’s experimental diabetes drug helps patients lose weight
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
Drugmakers may face ‘pay for delay’ suits, high court rules
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
Lilly to take over development of diabetes drug
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
Lilly halts trial of experimental Alzheimers drug
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
New law lets pharmacists provide pneumonia, HPV vaccines
Starting July 1, pharmacists will be able to offer a much wider variety of immunizations to customers, in an effort from lawmakers to make health care more accessible.
Lilly study: 1 in 5 Alzheimer’s patients misdiagnosed
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
Lilly stops development on cancer drug after failed study
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
Lilly’s sales-force restructuring to affect 1,600-plus
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
Lilly taking hard look at Pfizer’s new Viagra strategy
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.